Using AI to detect and predict eye damage from hydroxychloroquine

Artificial intelligence in the detection and prediction of hydroxychloroquine maculopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN11308648

Enrollment

100

Registered

2025-02-20

Start date

2024-08-01

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hydroxychloroquine maculopathy Eye Diseases

Interventions

Patients on long-term hydroxychloroquine (HCQ) therapy will have an optical coherence tomography (OCT) examination. Controls (no HCQ maculopathy) and toxicity (HCQ maculopathy) will be selected. OCT s

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Case group: Patients with diagnosis of HCQ or Chloroquine toxicity Control group: Patients with > 10 years of HCQ intake

Exclusion criteria

Exclusion criteria: Patients with ocular diseases that may mimic HCQ maculopathy or interfere with its screening

Design outcomes

Primary

Measure	Time frame
Age, sex, weight, total cumulative HCQ/CHLOROQUINE dose; daily HCQ/CHLOROQUINE dose, time of HCQ/CHLOROQUINE use, baseline disease for HCQ/CHLOROQUINE , Other systemic diseases, Steroid use and dose, immunosuppressant, other medications and dose, ocular disease, ocular medication collected from patients notes as well as interviews during normal consultations	—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

Portugal

Contacts

Public ContactRita Anjos

Rita.anjos@ulssjose.min-saude.pt+351 935619454

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026